**PCT** WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
**C07D 471/04, 471/10, A61K 31/44 // (C07D 471/04, 221:00, 221:00) (C07D 471/10, 221:00, 221:00)**

**A1**

(11) International Publication Number: **WO 99/65903**

(43) International Publication Date: 23 December 1999 (23.12.99)

(21) International Application Number: PCT/GB99/01826

(22) International Filing Date: 9 June 1999 (09.06.99)

(30) Priority Data:
9812683.2 12 June 1998 (12.06.98) GB

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: HARLING, John, David [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HARRINGTON, Frank, Peter [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published**
*With international search report.*

(54) Title: TETRAHYDRONAPHTHYRIDINYL-CARBOXAMIDES HAVING ANTI-CONVULSANT ACTIVITY



(I)

(57) Abstract

Compounds of formula (I) and pharmaceutically acceptable salts and solvates: where $R^1$ is hydrogen, $C_{1-6}$alkyl (optionally substituted by hydroxy or $C_{1-4}$alkoxy), phenyl–$C_{1-4}$alkyl–, $C_{1-6}$alkenyl, $C_{1-6}$alkynyl; $R^2$ is hydrogen or up to three substituents selected from halogen, $NO_2$, CN, $N_3$, $CF_3O$–, $CF_3S$–, $CF_3SO_2$–, $CF_3CO$–, $C_{1-6}$alkyl, $C_{1-6}$alkenyl, $C_{1-6}$alkynyl, $C_{1-6}$perfluoroalkyl, $C_{3-6}$cycloalkyl, $C_{3-6}$cycloalkyl–$C_{1-4}$alkyl–, $C_{1-6}$alkylO–, $C_{1-6}$alkylCO–, $C_{3-6}$cycloalkylO–, $C_{3-6}$cycloalkylCO–, $C_{3-6}$cycloalkyl–$C_{1-4}$alkylO–, $C_{3-6}$cycloalkyl–$C_{1-4}$alkylCO–, phenyl, phenoxy, benzyloxy, benzoyl, phenyl–$C_{1-4}$alkyl–, $C_{1-6}$alkylS–, $C_{1-6}$alkylSO$_2$–, ($C_{1-4}$alkyl)$_2$NSO$_2$–, ($C_{1-4}$alkyl)NHSO$_2$–, ($C_{1-4}$alkyl)$_2$NCO–, ($C_{1-4}$alkyl)NHCO– or $CONH_2$; or $-NR^5R^6$ where $R^5$ is hydrogen or $C_{1-4}$alkyl, and $R^6$ is hydrogen, $C_{1-4}$alkyl, formyl, $-CO_2C_{1-4}$alkyl or $-COC_{1-4}$alkyl; or two $R^2$ groups together form a carbocyclic ring that is saturated or unsaturated, optionally interrupted by O or NH; $R^3$ groups and $R^4$ groups are each independently hydrogen or $C_{1-6}$alkyl and/or the two $R^3$ groups and/or the two $R^4$ groups together form a $C_{3-6}$spiroalkyl group, provided that at least one $R^3$ or $R^4$ group is not hydrogen; and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy, are useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.